{"id":"NCT02873208","sponsor":"Alkermes, Inc.","briefTitle":"A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia","officialTitle":"A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-07","primaryCompletion":"2019-10-17","completion":"2019-10-17","firstPosted":"2016-08-19","resultsPosted":"2021-07-21","lastUpdate":"2021-07-21"},"enrollment":266,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"ALKS 3831","otherNames":[]}],"arms":[{"label":"ALKS 3831","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 3831 in subjects with schizophrenia.","primaryOutcome":{"measure":"Number of Subjects With Adverse Events","timeFrame":"Up to 52 weeks","effectByArm":[{"arm":"ALKS 3831","deltaMin":161,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":45,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":265},"commonTop":["Weight decreased","Extra dose administered","Headache","Weight increased","Upper respiratory tract infection"]}}